Neuropsychiatric Disease and Treatment (Aug 2022)
Pharmacological Management of Core Symptoms and Comorbidities of Autism Spectrum Disorder in Children and Adolescents: A Systematic Review
Abstract
Jennal Maniram,1 Saira BS Karrim,1 Frasia Oosthuizen,1 Ebenezer Wiafe1,2 1School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa; 2Clinical Pharmacy Services Unit, Directorate of Pharmacy, Ho Teaching Hospital, Ho, GhanaCorrespondence: Jennal Maniram, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa, Tel +27718931508, Email [email protected]: The pharmacological management of Autism Spectrum Disorder (ASD) in children remains a challenge due to limited effective management options and the absence of approved drugs to manage the core symptoms. This review aims to describe and highlight effective pharmacological management options employed in managing the core symptoms and comorbidities of ASD from eligible studies over the past decade.Methods: A search of databases; PubMed, Scopus, Science Direct, and PsychInfo for pharmacotherapeutic options for ASD was conducted in this systematic review. Duplicate studies were removed by utilizing the EndNote citation manager. The studies were subsequently screened independently by two authors. Eligible studies from 01 January 2012 to 01 January 2022 were included based on established eligibility criteria. A narrative synthesis was used for data analysis.Results: The systematic review provides a comprehensive list of effective management options for ASD comorbidities and core symptoms from 33 included studies. The management options for ASD comorbidities; insomnia, hyperactivity, irritability and aggression, gastrointestinal disturbances, and subclinical epileptiform discharges, were reviewed. Risperidone, aripiprazole, methylphenidate, guanfacine, levetiracetam, and atomoxetine are examples of effective pharmacological drugs against ASD comorbidities. Additionally, this review identified various drugs that improve the core symptoms of ASD and include but are not limited to, bumetanide, buspirone, intranasal oxytocin, intranasal vasopressin, and prednisolone.Conclusion: This review has successfully summarized the pharmacological advancements made in the past decade to manage ASD. Although there is still no pharmacological cure for ASD core symptoms or additional drugs that have obtained regulatory approval for use in ASD, the availability of promising pharmacological agents are under evaluation and study.Keywords: pharmacotherapy, therapeutic agent, effectiveness, outcome measure, randomized clinical trial, narrative synthesis
